| Year |
Citation |
Score |
| 2024 |
Comen E, Budhu S, Elhanati Y, Page D, Rasalan-Ho T, Ritter E, Wong P, Plitas G, Patil S, Brogi E, Jochelson M, Bryce Y, Solomon SB, Norton L, Merghoub T, et al. Preoperative immune checkpoint inhibition and cryoablation in early-stage breast cancer. Iscience. 27: 108880. PMID 38333710 DOI: 10.1016/j.isci.2024.108880 |
0.335 |
|
| 2023 |
Manning-Geist BL, Gnjatic S, Aghajanian C, Konner J, Kim SH, Sarasohn D, Soldan K, Tew WP, Sarlis NJ, Zamarin D, Kravetz S, Laface I, Rasalan-Ho T, Qi J, Wong P, et al. Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission. Cancers. 15. PMID 36900251 DOI: 10.3390/cancers15051458 |
0.301 |
|
| 2022 |
Holm JS, Funt SA, Borch A, Munk KK, Bjerregaard AM, Reading JL, Maher C, Regazzi A, Wong P, Al-Ahmadie H, Iyer G, Tamhane T, Bentzen AK, Herschend NO, De Wolf S, et al. Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. Nature Communications. 13: 1935. PMID 35410325 DOI: 10.1038/s41467-022-29342-0 |
0.399 |
|
| 2020 |
Kelly CM, Antonescu CR, Bowler T, Munhoz R, Chi P, Dickson MA, Gounder MM, Keohan ML, Movva S, Dholakia R, Ahmad H, Biniakewitz M, Condy M, Phelan H, Callahan M, ... Wong P, et al. Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial. Jama Oncology. PMID 31971541 DOI: 10.1001/Jamaoncol.2019.6152 |
0.436 |
|
| 2020 |
Holm JS, Funt SA, Bjerregaard A, Reading JL, Maher CA, Regazzi AM, Wong P, Al-Ahmadie H, Overgaard NH, Tamhane T, Bentzen AK, Snyder A, Merghoub T, Wolchok JD, Nielsen M, et al. Interrogation of neoantigen-specific CD8 T cells in peripheral blood following PD-L1 blockade in patients with metastatic urothelial carcinoma (mUC). Journal of Clinical Oncology. 38: 3075-3075. DOI: 10.1200/Jco.2020.38.15_Suppl.3075 |
0.474 |
|
| 2019 |
Verma V, Shrimali RK, Ahmad S, Dai W, Wang H, Lu S, Nandre R, Gaur P, Lopez J, Sade-Feldman M, Yizhak K, Bjorgaard SL, Flaherty KT, Wargo JA, Boland GM, ... ... Wong P, et al. Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1CD38 cells and anti-PD-1 resistance. Nature Immunology. PMID 31551574 DOI: 10.1038/S41590-019-0519-6 |
0.329 |
|
| 2019 |
Verma V, Shrimali RK, Ahmad S, Dai W, Wang H, Lu S, Nandre R, Gaur P, Lopez J, Sade-Feldman M, Yizhak K, Bjorgaard SL, Flaherty KT, Wargo JA, Boland GM, ... ... Wong P, et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1CD38 cells and anti-PD-1 resistance. Nature Immunology. PMID 31358999 DOI: 10.1038/S41590-019-0441-Y |
0.366 |
|
| 2019 |
Zappasodi R, Sirard C, Li Y, Budhu S, Abu-Akeel M, Liu C, Yang X, Zhong H, Newman W, Qi J, Wong P, Schaer D, Koon H, Velcheti V, Hellmann MD, et al. Rational design of anti-GITR-based combination immunotherapy. Nature Medicine. PMID 31036879 DOI: 10.1038/S41591-019-0420-8 |
0.463 |
|
| 2019 |
Zappasodi R, Sirard C, Li Y, Budhu S, Abu-Akeel M, Liu C, Yang X, Zhong H, Newman W, Qi J, Wong P, Schaer D, Koon H, Velcheti V, Postow M, et al. Abstract PR01: Mechanistic rationale to combine GITR agonism with PD-1 blockade in cancer patients Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-Pr01 |
0.469 |
|
| 2019 |
Oft M, Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, Autio KA, Wong DJ, Patel MR, Ott PA, Falchook GS, Pant S, Hung A, Mumm JB, ... ... Wong P, et al. Abstract A016: PEGylated IL-10 (pegilodecakin) induces systemic immune activation, CD8+ T-cell invigoration and polyclonal T-cell expansion in cancer patients Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A016 |
0.487 |
|
| 2018 |
Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, Rojo B, Autio KA, Wong DJ, Patel MR, Ott PA, Falchook GS, Pant S, Hung A, Pekarek KL, ... ... Wong P, et al. PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8 T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. Cancer Cell. 34: 775-791.e3. PMID 30423297 DOI: 10.1016/J.Ccell.2018.10.007 |
0.512 |
|
| 2018 |
Vorkas CK, Wipperman MF, Li K, Bean J, Bhattarai SK, Adamow M, Wong P, Aubé J, Juste MAJ, Bucci V, Fitzgerald DW, Glickman MS. Mucosal-associated invariant and γδ T cell subsets respond to initial Mycobacterium tuberculosis infection. Jci Insight. 3. PMID 30282828 DOI: 10.1172/Jci.Insight.121899 |
0.369 |
|
| 2018 |
O'Cearbhaill RE, Gnjatic S, Aghajanian C, Iasonos A, Konner JA, Losada N, Sarasohn D, Rasalan T, Tew WP, Zamarin D, Wong P, Sabbatini P. A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission. Journal of Clinical Oncology. 36: 5553-5553. DOI: 10.1200/Jco.2018.36.15_Suppl.5553 |
0.31 |
|
| 2017 |
Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. PMID 28397821 DOI: 10.1038/Nature22079 |
0.439 |
|
| 2017 |
Wistuba-Hamprecht K, Martens A, Heubach F, Romano E, Geukes Foppen M, Yuan J, Postow M, Wong P, Mallardo D, Schilling B, Di Giacomo AM, Khammari A, Dreno B, Maio M, Schadendorf D, et al. Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. European Journal of Cancer (Oxford, England : 1990). 73: 61-70. PMID 28167454 DOI: 10.1016/J.Ejca.2016.12.011 |
0.448 |
|
| 2017 |
Callahan MK, Kania BE, Iyer G, Clement JM, Funt S, McCoy AS, Hettich G, Ziv E, Bluth MJ, Wong P, Wolchok JD, Bajorin DF, Rosenberg JE. Evaluation of the clinical activity of ipilimumab (IPI) plus nivolumab (NIVO) in patients (pts) with NIVO-refractory metastatic urothelial cancer (UC). Journal of Clinical Oncology. 35: 384-384. DOI: 10.1200/Jco.2017.35.6_Suppl.384 |
0.312 |
|
| 2017 |
Funt S, Mu Z, Cipolla CK, Kania BE, Zheng J, Boyd ME, Charen AS, Callahan MK, Autio KA, Regazzi AM, Moran MM, Ostrovnaya I, Iyer G, Wong P, Lesokhin AM, et al. Evaluation of monocytic myeloid-derived suppressor cell (M-MDSC) frequency in patients with metastatic urothelial carcinoma (mUC). Journal of Clinical Oncology. 35: 356-356. DOI: 10.1200/Jco.2017.35.6_Suppl.356 |
0.327 |
|
| 2016 |
Page DB, Yuan J, Redmond D, Wen YH, Durack JC, Emerson R, Solomon SB, Dong Z, Wong P, Comstock C, Diab A, Sung J, Maybody M, Morris EA, Brogi E, et al. Deep Sequencing of T-Cell Receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy. Cancer Immunology Research. PMID 27587469 DOI: 10.1158/2326-6066.Cir-16-0013 |
0.426 |
|
| 2016 |
Wistuba-Hamprecht K, Martens A, Haehnel K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Demuth I, Steinhagen-Thiessen E, Larbi A, et al. Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. European Journal of Cancer (Oxford, England : 1990). 64: 116-126. PMID 27400322 DOI: 10.1016/J.Ejca.2016.06.001 |
0.418 |
|
| 2016 |
Martens A, Wistuba-Hamprecht K, Yuan J, Postow MA, Wong P, Capone M, Madonna G, Khammari A, Schilling B, Sucker A, Schadendorf D, Martus P, Dreno B, Ascierto PA, Wolchok JD, et al. Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27169993 DOI: 10.1158/1078-0432.Ccr-16-0249 |
0.401 |
|
| 2016 |
Jacquelot N, Enot DP, Flament C, Vimond N, Blattner C, Pitt JM, Yamazaki T, Roberti MP, Daillère R, Vétizou M, Poirier-Colame V, Semeraro M, Caignard A, Slingluff CL, Sallusto F, ... ... Wong P, et al. Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. The Journal of Clinical Investigation. PMID 26854930 DOI: 10.1172/Jci80071 |
0.468 |
|
| 2016 |
Martens A, Wistuba-Hamprecht K, Geukes Foppen MH, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Di Giacomo AM, Maio M, Schilling B, Sucker A, et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26787752 DOI: 10.1158/1078-0432.Ccr-15-2412 |
0.388 |
|
| 2016 |
Postow MA, Kuk D, Adamow M, Carrera C, Wong P, Curran MA, Friedman CF, Momtaz P, Shoushtari AN, Wolchok JD, Chapman PB, Callahan MK. Peripheral blood T cell subset phenotype analysis in melanoma patients treated with combination nivolumab + ipilimumab compared to ipilimumab alone. Journal of Clinical Oncology. 34: 3073-3073. DOI: 10.1200/Jco.2016.34.15_Suppl.3073 |
0.367 |
|
| 2016 |
Huang A, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Adamow M, Kuk D, Panangeas K, Carerra C, Wong P, Quagliarello F, Pauken KE, et al. Abstract PR05: Peripheral blood immune profiling of anti-PD-1 therapy in human melanoma reveals a link between T cell re-invigoration and tumor burden that predicts response Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-Pr05 |
0.441 |
|
| 2015 |
Postow MA, Manuel M, Wong P, Yuan J, Dong Z, Liu C, Perez S, Tanneau I, Noel M, Courtier A, Pasqual N, Wolchok JD. Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. Journal For Immunotherapy of Cancer. 3: 23. PMID 26085931 DOI: 10.1186/S40425-015-0070-4 |
0.393 |
|
| 2015 |
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York, N.Y.). 348: 124-8. PMID 25765070 DOI: 10.1126/Science.Aaa1348 |
0.403 |
|
| 2015 |
Autio KA, Wong P, Rabinowitz A, Yuan J, Slavin LM, Brennan R, DerSarkissian M, Mu Z, Scher HI, Lesokhin AM. Presence of myeloid-derived suppressor cells (MDSC) in patients with metastatic castration-sensitive and castration-resistant prostate cancer. Journal of Clinical Oncology. 33: 222-222. DOI: 10.1200/Jco.2015.33.7_Suppl.222 |
0.346 |
|
| 2015 |
Page D, Yuan J, Diab A, Dong Z, Ginsberg A, Wong P, Emerson R, Redmond D, Blum B, Mu Z, Zhao C, Comstock C, Morris E, Comen E, Kotin A, et al. Abstract P2-15-01: Integrated immunologic assessment of tumor infiltrating lymphocytes (TILs) and peripheral blood to assess synergy of cryoablation (cryo) plus ipilimumab (ipi) in early stage breast cancer (ESBC) patients (pts) Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P2-15-01 |
0.498 |
|
| 2014 |
Yuan J, Ginsberg A, Dong Z, Wong P, Emerson R, Sung JS, Comstock C, Solomon SB, Sacchini V, Morrow M, Brogi E, Morris EA, Patil S, Robins H, Wolchok JD, et al. Tumor and systemic immune responses to preoperative (pre-op) cryoablation (cryo) plus immune therapy with ipilimumab (ipi) in early-stage breast cancer (ESBC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 64. PMID 28141090 DOI: 10.1200/Jco.2014.32.26_Suppl.64 |
0.362 |
|
| 2014 |
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. The New England Journal of Medicine. 371: 2189-99. PMID 25409260 DOI: 10.1056/Nejmoa1406498 |
0.457 |
|
| 2014 |
Kitano S, Postow MA, Ziegler CG, Kuk D, Panageas KS, Cortez C, Rasalan T, Adamow M, Yuan J, Wong P, Altan-Bonnet G, Wolchok JD, Lesokhin AM. Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. Cancer Immunology Research. 2: 812-21. PMID 24844912 DOI: 10.1158/2326-6066.Cir-14-0013 |
0.397 |
|
| 2014 |
Postow M, Manuel M, Wong P, Yuan J, Courtier A, Pasqual N, Wolchok JD. T cell receptor diversity evaluation to predict patient response to ipilimumab in metastatic melanoma F1000research. 5. DOI: 10.7490/F1000Research.1097399.1 |
0.393 |
|
| 2014 |
Page DB, Diab A, Yuan J, Dong Z, Emerson R, Robins H, Redmond D, Zhao C, Mu Z, Wong P, Solomon SB, Sacchini V, Morrow M, Brogi E, Patil S, et al. T-cell receptor (TCR) DNA deep sequencing to evaluate clonality of tumor-infiltrating lymphocytes (TILs) in early-stage breast cancer patients (pts) receiving preoperative cryoablation (cryo) and/or ipilimumab (ipi). Journal of Clinical Oncology. 32: 3021-3021. DOI: 10.1200/Jco.2014.32.15_Suppl.3021 |
0.405 |
|
| 2014 |
Page DB, McArthur H, Dong Z, Wong P, Emerson R, Mu Z, Zhao C, Comstock C, Morris E, Comen E, Kotin A, Sung J, Brogi E, Morrow M, Solomon S, et al. Matched T cell repertoire analysis of peripheral blood and tumor-infiltrating lymphocytes (TILs) in early stage breast cancer (ESBC) patients (pts) treated with pre-operative cryoablation (cryo) and/or Ipilimumab (Ipi) Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P138 |
0.426 |
|
| 2014 |
Postow M, Manuel M, Wong P, Yuan J, Noel M, Courtier A, Pasqual N, Wolchok JD. T cell receptor diversity evaluation to predict patient response to Ipilimumab in metastatic melanoma. Journal For Immunotherapy of Cancer. 2: 1-2. DOI: 10.1186/2051-1426-2-S3-O8 |
0.373 |
|
| 2005 |
Beers C, Burich A, Kleijmeer MJ, Griffith JM, Wong P, Rudensky AY. Cathepsin S controls MHC class II-mediated antigen presentation by epithelial cells in vivo. Journal of Immunology (Baltimore, Md. : 1950). 174: 1205-12. PMID 15661874 DOI: 10.4049/Jimmunol.174.3.1205 |
0.707 |
|
| 2004 |
Yuan RR, Wong P, McDevitt MR, Doubrovina E, Leiner I, Bornmann W, O'reilly R, Pamer EG, Scheinberg DA. Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers. Blood. 104: 2397-402. PMID 15217835 DOI: 10.1182/Blood-2004-01-0324 |
0.494 |
|
| 2004 |
Wong P, Lara-Tejero M, Ploss A, Leiner I, Pamer EG. Rapid development of T cell memory. Journal of Immunology (Baltimore, Md. : 1950). 172: 7239-45. PMID 15187098 DOI: 10.4049/Jimmunol.172.12.7239 |
0.44 |
|
| 2004 |
Wong P, Pamer EG. Disparate in vitro and in vivo requirements for IL-2 during antigen-independent CD8 T cell expansion. Journal of Immunology (Baltimore, Md. : 1950). 172: 2171-6. PMID 14764683 DOI: 10.4049/Jimmunol.172.4.2171 |
0.421 |
|
| 2003 |
Wong P, Pamer EG. Feedback regulation of pathogen-specific T cell priming. Immunity. 18: 499-511. PMID 12705853 DOI: 10.1016/S1074-7613(03)00081-5 |
0.472 |
|
| 2003 |
Wong P, Pamer EG. CD8 T cell responses to infectious pathogens. Annual Review of Immunology. 21: 29-70. PMID 12414723 DOI: 10.1146/Annurev.Immunol.21.120601.141114 |
0.482 |
|
| 2002 |
Jung S, Unutmaz D, Wong P, Sano G, De los Santos K, Sparwasser T, Wu S, Vuthoori S, Ko K, Zavala F, Pamer EG, Littman DR, Lang RA. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity. 17: 211-20. PMID 12196292 DOI: 10.1016/S1074-7613(02)00365-5 |
0.484 |
|
| 2001 |
Wong P, Barton GM, Forbush KA, Rudensky AY. Dynamic tuning of T cell reactivity by self-peptide-major histocompatibility complex ligands Journal of Experimental Medicine. 193: 1179-1187. PMID 11369789 DOI: 10.1084/Jem.193.10.1179 |
0.718 |
|
| 2001 |
Wong P, Pamer EG. Cutting edge: Antigen-independent CD8 T cell proliferation Journal of Immunology. 166: 5864-5868. PMID 11342598 DOI: 10.4049/Jimmunol.166.10.5864 |
0.455 |
|
| 2000 |
Wong P, Goldrath AW, Rudensky AY. Competition for specific intrathymic ligands limits positive selection in a TCR transgenic model of CD4+ T cell development. Journal of Immunology (Baltimore, Md. : 1950). 164: 6252-9. PMID 10843678 DOI: 10.4049/Jimmunol.164.12.6252 |
0.61 |
|
| 1998 |
Nakagawa T, Roth W, Wong P, Nelson A, Farr A, Deussing J, Villadangos JA, Ploegh H, Peters C, Rudensky AY. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science (New York, N.Y.). 280: 450-3. PMID 9545226 DOI: 10.1126/Science.280.5362.450 |
0.657 |
|
| 1998 |
Liljedahl M, Winqvist O, Surh CD, Wong P, Ngo K, Teyton L, Peterson PA, Brunmark A, Rudensky AY, Fung-Leung WP, Karlsson L. Altered antigen presentation in mice lacking H2-O Immunity. 8: 233-243. PMID 9492004 DOI: 10.1016/S1074-7613(00)80475-6 |
0.578 |
|
| 1996 |
Wong P, Rudensky AY. Phenotype and function of CD4+ T cells in mice lacking invariant chain. Journal of Immunology (Baltimore, Md. : 1950). 156: 2133-42. PMID 8690902 |
0.616 |
|
| 1990 |
Tripathi BJ, Tripathi RC, Wong P, Raja S. Expression of HLA by the human trabecular meshwork and corneal endothelium. Experimental Eye Research. 51: 269-76. PMID 2205510 DOI: 10.1016/0014-4835(90)90023-N |
0.303 |
|
| Show low-probability matches. |